Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 5/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PLG | P00747 | 4/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.38 |
| ▸ | F10 | P00742 | 2/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2462330 | 0.96 | NPC1 (0.44) | IGF1RJAK2JAK1NPC1LMNA | |
| SCHEMBL2459519 | 0.94 | IGF1R (0.44) | IGF1RJAK2JAK1NPC1RAB9A | |
| SCHEMBL2461604 | 0.92 | IGF1R (0.51) | IGF1RJAK2JAK1NPC1RAB9A | |
| SCHEMBL2463470 | 0.91 | IGF1R (0.51) | IGF1RJAK2JAK1KDM4EF10 | |
| SCHEMBL2460711 | 0.89 | IGF1R (0.43) | IGF1RJAK2JAK1KDM4EF10 | |
| SCHEMBL2460832 | 0.89 | IGF1R (0.51) | IGF1RJAK2JAK1F10 | |
| SCHEMBL2458133 | 0.89 | IGF1R (0.41) | IGF1RJAK2JAK1LMNAKDM4E | |
| SCHEMBL2457374 | 0.88 | IGF1R (0.43) | IGF1RJAK2JAK1F10 | |
| SCHEMBL2460551 | 0.88 | IGF1R (0.48) | IGF1RJAK2JAK1NPC1RAB9A | |
| SCHEMBL2460224 | 0.87 | IGF1R (0.37) | IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675860-B1 | IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS | OSI PHARM INC (US) | 2011-09-21 | — | — | EP | claimed |
| EP-1675860-B1 | IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS | OSI PHARM INC (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20090181940-A1 | Imidazopyrazine Tyrosine Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20080227788-A9 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS | BECK PATRICIA A | 2008-09-18 | — | — | US | disclosed |
| US-20060084654-A1 | Imidazopyrazine tyrosine kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227788-A9 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS | IGF1R, IRS1, IGFBP1 | IGF1R 1/4885JAK2 9/4885JAK1 23/4885 |
| US-20060084654-A1 | Imidazopyrazine tyrosine kinase inhibitors | IGF1R, IRS1, IGFBP1 | IGF1R 1/4885JAK2 9/4885JAK1 23/4885 |
| US-20090181940-A1 | Imidazopyrazine Tyrosine Kinase Inhibitors | IGF1R, IRS1, IGFBP1 | IGF1R 1/4885JAK2 9/4885JAK1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.